A 6-Week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%
References (29)
- et al.
Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
Am J Ophthalmol
(2001) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States
Ophthalmology
(1996)- et al.
Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure
Surv Ophthalmol
(2001) - et al.
Anterior uveitis associated with latanoprost
Am J Ophthalmol
(1998) - et al.
Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients
Ophthalmology
(1998) - et al.
A comparison oflatanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study
Am J Ophthalmol
(2003) - et al.
Intraocular pressure lowering effect and safety of travoprost 0.004% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma
Asian J Glaucoma
(2006) - et al.
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells
J Ocul Pharmacol Ther
(2003) - et al.
The number of people with glaucoma worldwide in 2010 and 2020
Br J Ophthalmol
(2006) - et al.
The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Arch Ophthalmol.
(2002)
Reduction of intraocular pressure and glaucoma progression: Results From the Early Manifest Glaucoma Trial
Arch Ophthalmol
Management of glaucoma: Focus on pharmacological therapy
Drugs Aging
Prostanoids in the therapy of glaucoma
Cardiovasc Drug Rev
Glaucoma management trends in Australia and New Zealand
Clin Experiment Ophthalmol
Cited by (15)
Evaluation of investigator bias in industry-funded clinical trials of latanoprost
2011, Canadian Journal of OphthalmologyCitation Excerpt :Because of the low number of eligible data sets for bimatoprost and travoprost, statistical analysis was performed only for the latanoprost IOP data sets (47 IOP data sets from 38 articles) (Table 1). The 33 IOP data sets from 29 articles (4 studies were cross-over designs and contributed 2 IOP data sets each) investigating latanoprost provided 1-month data,4,6,8,9,12-36 and 14 data sets from 13 articles (1 study was a cross-over design and contributed 2 data sets) provided 3-month data.7-10,15,18,37-43 Details of the latanoprost studies are provided in Table 2.
Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis
2009, Current Therapeutic Research - Clinical and ExperimentalCommercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences
2008, Survey of OphthalmologyCitation Excerpt :A final aspect to consider when reviewing studies is the difference between statistical and clinical significance, a distinction acknowledged by Konstas et al.79 For IOP-lowering therapy, the FDA considers clinical relevance to be a between-treatment difference greater than 1.5 mm Hg. Using mean diurnal IOP at the final visit as the primary endpoint, all but one of the studies summarized in Table 2 demonstrated a between-treatment difference of less than 1.5 mm Hg.1,30,33,34,36,43,46,47,53,55,57,68,78–80,90,93,95,96,99,102,103,145,158 The exception was the study by Parmaksiz et al102 that found a difference of 1.7 mm Hg in favor of latanoprost over travoprost.
Intraocular Pressure Lowering Effect of Latanoprost as First-line Treatment for Glaucoma
2018, Journal of GlaucomaMedical treatment: First-line agents, monotherapy, and combination therapy
2016, Pearls of Glaucoma Management: Second Edition